News » Visby Medical Makes Strategic Hires to Continue Business Development

07/16/2021Press Release

Visby Medical Makes Strategic Hires to Continue Business Development

Visby Medical appoints Mark Ibison as Chief Financial Officer, Christopher J. Jowett as Chief Commercial Officer, and Alicia Zuiker as Chief People Officer

Visby Medical Makes Strategic Hires to Continue Business Development

(From left to right): Chief Commercial Officer Christopher J. Jowett, Chief Financial Officer Mark Ibison, and Chief People Officer Alicia Zuiker.

(SAN JOSE, CA), July 16, 2021  – Today, Visby Medical, a leading medical diagnostic company, announced three strategic new hires – Mark Ibison as Chief Financial Officer, Christopher J. Jowett as Chief Commercial Officer, and Alicia Zuiker as Chief People Officer. All three will join the executive leadership team to address key areas of growth and development for the company and its signature diagnostic tests for COVID-19 and sexual health.

“In the last year, Visby Medical has seen exponential growth with our innovative PCR technology,” said Adam de la Zerda, CEO of Visby Medical. “We’re delighted to have Mark, Christopher and Alicia join the team as each of these leaders brings unique experiences and acumen that will help Visby achieve its business goals.”

Mark has over 20 years of financial management and planning across biotech and diagnostics sectors with extensive experience developing effective financial models that drive performance. Most recently, he held the position of Chief Financial Officer for Mesa Biotech, a healthcare company that utilizes rapid-PCR to provide results for infectious disease testing. Previously, he was the Chief Financial Officer for SOLVD Health and Vice President of Finance for Thermo Fisher Biosciences. Mark is currently an associate member of the Chartered Institute of Management Accountants and the Association of Corporate Treasurers.

Christopher joins Visby with in-depth knowledge of the diagnostics sector and over 30 years of sales, marketing, and operational leadership experience. He was previously Vice President of Molecular Diagnostic Sales, North America, at QIAGEN Inc., a provider of sample and assay technologies of molecular diagnostics, and has held various leadership roles within Abbott Laboratories. Christopher has proven success in driving business outcomes in the diagnostics industry and will be essential to Visby’s growth as they continue to deliver new products and innovations.

Alicia will step into her role bringing over 16 years of experience in human resources – spanning organizational design and transformation, culture and talent management, executive coaching, and Diversity, Equity & Inclusion (DE&I) expertise. Most recently, she held the position of Director People Operations, Customer Experience at Google, and prior to that, she was VP of Human Resources at GE. Alicia will be crucial in helping build and define our culture, growing teams, and fostering individual growth to meet our collective business objectives.

About Visby Medical™

Visby Medical has been working to change the order of diagnosis and treatment of infectious disease for a decade. Visby Medical has a single-use PCR test to rapidly test for serious infections. Tested, reviewed, and endorsed by top public and private organizations, the first commercial application of the Visby Medical technology received FDA Emergency Use Authorization in 2020 for moderate-complexity laboratory testing of symptomatic patients in the fight against COVID-19, and in 2021 for use in settings with a CLIA Certificate of Waiver. Visby is gaining government and private partnerships to accelerate the delivery of PCR-grade diagnostics, designed for use at the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedIn at www.linkedin.com/company/visbymedical; Facebook, Instagram, and Twitter @VisbyMedical.

Contact: (240) 839-0945 | press@visby.com

Read more articles & insights

12/01/2023Viewpoint

Bracing for Winter Surges: The Imperative of PCR Point-of-Care Testing in Urgent Cares

As the chill in the air intensifies, healthcare systems worldwide brace themselves for a seasonal upswing in respiratory illnesses. This year, the situation is exacerbated by the continuing threat of COVID-19 alongside the potential resurgence of seasonal influenza (Flu A and Flu B).

Read More
Bracing for Winter Surges: The Imperative of PCR Point-of-Care Testing in Urgent Cares

11/18/2023Viewpoint

A Case Study on the Importance of Testing: When SARS-CoV-2 Meets Influenza A

In the setting of a global pandemic, the specter of SARS-CoV-2 infection has understandably dominated the differential diagnosis for respiratory symptoms. However, it is crucial to remember that other respiratory pathogens continue to circulate, potentially leading to varied clinical presentations in patients who share the same exposure or living environment.

Read More
A Case Study on the Importance of Testing: When SARS-CoV-2 Meets Influenza A

05/11/2023Viewpoint

Navigating the Post-Public Health Emergency Landscape: How the Visby Medical Respiratory Health Test EUA Remains Unaffected

As we move into the post-public health emergency landscape with the expiration of the national emergency concerning the coronavirus disease 2019 (COVID-19) pandemic on May 11, 2023, it is essential to understand how the healthcare industry has adapted and evolved to address the unique challenges posed by the COVID-19 pandemic.

Read More
Navigating the Post-Public Health Emergency Landscape: How the Visby Medical Respiratory Health Test EUA Remains Unaffected

03/14/2023Press Release

Visby Medical™ Receives FDA Clearance and CLIA Waiver for second Generation Sexual Health Test for Women

Visby Medical™ announced today that it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its 2nd generation point of care (POC) test.

Read More
Visby Medical™ Receives FDA Clearance and CLIA Waiver for second Generation Sexual Health Test for Women